CY1110363T1 - Παραγωγα (1-4-πιπεριδινυλ)βενζιμιδαζολιου χρησιμα σαν ανταγωνιστες η3 ισταμινης - Google Patents

Παραγωγα (1-4-πιπεριδινυλ)βενζιμιδαζολιου χρησιμα σαν ανταγωνιστες η3 ισταμινης

Info

Publication number
CY1110363T1
CY1110363T1 CY20081100604T CY081100604T CY1110363T1 CY 1110363 T1 CY1110363 T1 CY 1110363T1 CY 20081100604 T CY20081100604 T CY 20081100604T CY 081100604 T CY081100604 T CY 081100604T CY 1110363 T1 CY1110363 T1 CY 1110363T1
Authority
CY
Cyprus
Prior art keywords
formula
histamine
antagonists
compounds
disclosed
Prior art date
Application number
CY20081100604T
Other languages
English (en)
Inventor
Qingbei Zeng
Robert G. Aslanian
Michael Y. Berlin
Christopher W. Boyce
Jianhua Cao
Joseph A. Kozlowski
Pietro Mangiaracina
Kevin D. Mc Cormick
Mwangi M MUTAHI
Stuart B. Rosenblum
Neng-Yang Shih
Daniel M. Solomon
Wing C. Tom
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of CY1110363T1 publication Critical patent/CY1110363T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Αποκαλύπτονται ανταγωνιστές Η3 ισταμίνης του τύπου (I) όπου το R1 προαιρετικά είναι υποκατεστημένο βενζιμιδαζολυλ ή παράγωγο αυτού, το R2 είναι προαιρετικά υποκατεστημένο αρυλ ή ετεροαρυλ, τα Μ1 και Μ2 είναι C(R3) ή Ν, το Q είναι -N(R8)-, -S- ή -Ο- και οι υπόλοιπες μεταβλητές είναι όπως ορίζονται στην περιγραφή. Επίσης αποκαλύπτονται φαρμακευτικές συνθέσεις που περιλαμβάνουν τις ενώσεις του τύπου I και μεθόδους θεραπείας διαφόρων ασθενειών ή καταστάσεων, όπως αλλεργίες, διεγειρόμενων από αλλεργία αποκρίσεων αεροδού και συμφόρησης (π.χ., ρινικής συμφόρησης) χρησιμοποιώντας τις ενώσεις του τύπου I. Επίσης αποκαλύπτονται μέθοδοι θεραπείας των εν λόγω ασθενειών ή καταστάσεων χρησιμοποιώντας τις ενώσεις του τύπου I σε συνδυασμό με ανταγωνιστή υποδοχέα H1.
CY20081100604T 2002-04-18 2008-06-09 Παραγωγα (1-4-πιπεριδινυλ)βενζιμιδαζολιου χρησιμα σαν ανταγωνιστες η3 ισταμινης CY1110363T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37373102P 2002-04-18 2002-04-18
PCT/US2003/011672 WO2003088967A1 (en) 2002-04-18 2003-04-16 (1-4-piperidinyl) benzimidazole derivatives useful as histamine h3 antagonists

Publications (1)

Publication Number Publication Date
CY1110363T1 true CY1110363T1 (el) 2012-05-23

Family

ID=29251069

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100604T CY1110363T1 (el) 2002-04-18 2008-06-09 Παραγωγα (1-4-πιπεριδινυλ)βενζιμιδαζολιου χρησιμα σαν ανταγωνιστες η3 ισταμινης

Country Status (27)

Country Link
EP (1) EP1499316B1 (el)
JP (1) JP4384918B2 (el)
KR (1) KR100827470B1 (el)
CN (1) CN100522166C (el)
AR (1) AR040405A1 (el)
AT (1) ATE389406T1 (el)
AU (1) AU2003223627B2 (el)
BR (1) BR0309348A (el)
CA (1) CA2481940A1 (el)
CY (1) CY1110363T1 (el)
DE (1) DE60319813T2 (el)
DK (1) DK1499316T3 (el)
EC (1) ECSP045367A (el)
ES (1) ES2301791T3 (el)
HK (1) HK1067981A1 (el)
IL (1) IL164584A (el)
MX (1) MXPA04010173A (el)
NO (1) NO20045002L (el)
NZ (1) NZ535763A (el)
PE (1) PE20040684A1 (el)
PL (1) PL373889A1 (el)
PT (1) PT1499316E (el)
RU (1) RU2323935C2 (el)
SI (1) SI1499316T1 (el)
TW (1) TW200306183A (el)
WO (1) WO2003088967A1 (el)
ZA (1) ZA200407984B (el)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4613157B2 (ja) 2003-01-14 2011-01-12 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
TW200503713A (en) 2003-04-23 2005-02-01 Glaxo Group Ltd Novel compounds
EP1765327B1 (en) 2004-06-17 2014-08-13 Cytokinetics, Inc. Compounds, compositions and methods
US7176222B2 (en) 2004-07-27 2007-02-13 Cytokinetics, Inc. Syntheses of ureas
WO2006038738A1 (ja) * 2004-10-08 2006-04-13 Takeda Pharmaceutical Company Limited 受容体機能調節剤
CN101107231A (zh) * 2005-01-21 2008-01-16 先灵公司 用作组胺h3拮抗剂的咪唑和苯并咪唑衍生物
CN101243072A (zh) 2005-06-20 2008-08-13 先灵公司 用作组胺h3拮抗剂的哌啶衍生物
JP2008543940A (ja) * 2005-06-20 2008-12-04 シェーリング コーポレイション ヒスタミンh3アンタゴニストとして有用な、炭素結合した置換ピペリジンおよびその誘導体
US7538223B2 (en) 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
JP4860700B2 (ja) * 2005-09-20 2012-01-25 シェーリング コーポレイション ヒスタミンH3アンタゴニストとして有用な、1−[[1−[(2−アミノ−6−メチル−4−ピリジニル)メチル]−4−フルオロ−4−ピペリジニル]カルボニル]−4−[2−(2−ピリジニル)−3H−イミダゾ[4,5−b]ピリジン−3−イル]ピペリジン
CN101273026A (zh) * 2005-09-30 2008-09-24 霍夫曼-拉罗奇有限公司 作为mch受体拮抗剂的茚满衍生物
AR058347A1 (es) 2005-12-15 2008-01-30 Cytokinetics Inc Entidades quimias composiciones y metodos
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
US7718657B2 (en) 2005-12-16 2010-05-18 Cytokinetics, Inc. Certain indanyl urea modulators of the cardiac sarcomere
WO2007078839A2 (en) 2005-12-19 2007-07-12 Cytokinetics, Inc. Compounds, compositions and methods
PE20071162A1 (es) * 2005-12-21 2007-11-30 Schering Corp Combinacion de un antagonista/agonista inverso de h3 y un supresor del apetito
JP2009521448A (ja) 2005-12-21 2009-06-04 シェーリング コーポレイション ヒスタミンh3アンタゴニストとして有用なフェノキシピペリジンおよびそのアナログ
AU2007204426A1 (en) * 2006-01-13 2007-07-19 F. Hoffmann-La Roche Ag Cyclohexyl piperazinyl methanone derivatives and their use as histamine H3 receptor modulators
TW200813018A (en) 2006-06-09 2008-03-16 Astrazeneca Ab Novel compounds
US8119661B2 (en) 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
CN101809021B (zh) * 2007-09-11 2013-04-24 雅培制药有限公司 八氢-吡咯并[3,4-b]吡咯n-氧化物
GB0813142D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB0813144D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
CN102781940B (zh) 2009-12-30 2016-09-07 艾科尔公司 取代的咪唑并吡啶基-氨基吡啶化合物
WO2012177852A1 (en) 2011-06-24 2012-12-27 Arqule, Inc Substituted imidazopyridinyl compounds
CA2837727C (en) 2011-06-24 2019-12-03 Arqule, Inc. Substituted imidazopyridinyl-aminopyridine compounds
KR101127756B1 (ko) 2011-09-02 2012-03-23 한국과학기술원 Git1 유전자 결손 마우스 및 이를 이용한 약물 스크리닝 방법
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
JP6046646B2 (ja) 2014-01-10 2016-12-21 信越化学工業株式会社 オニウム塩、化学増幅型ポジ型レジスト組成物、及びパターン形成方法
US10595550B2 (en) * 2014-01-22 2020-03-24 Vision Pharma, Llc Therapeutic composition including carbonated solution
US10118900B2 (en) 2015-08-25 2018-11-06 Janssen Pharmaceutica Nv Benzimidazole derivatives useful as CB-1 inverse agonists
KR20210145787A (ko) 2019-04-02 2021-12-02 알리고스 테라퓨틱스 인코포레이티드 Prmt5를 표적으로 하는 화합물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2048109B1 (es) * 1992-07-20 1994-12-16 Espanola Prod Quimicos Procedimiento de preparacion de nuevos derivados piperidicos del bencimidazol.
EP0626373B1 (en) * 1993-05-26 1998-12-23 Sumitomo Pharmaceuticals Company, Limited Quinazolinone derivatives
US6211199B1 (en) * 1995-11-17 2001-04-03 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
AU2001292730A1 (en) * 2000-09-20 2002-04-02 Schering Corporation Substituted imidazoles as dual histamine h1 and h3 agonists or antgonists
ATE529112T1 (de) * 2002-04-18 2011-11-15 Schering Corp 1-(4-piperidinyl)benzimidazolone als histamin h3 antagonisten

Also Published As

Publication number Publication date
BR0309348A (pt) 2005-03-01
IL164584A (en) 2010-12-30
AR040405A1 (es) 2005-04-06
NO20045002L (no) 2005-01-18
EP1499316A1 (en) 2005-01-26
RU2323935C2 (ru) 2008-05-10
PL373889A1 (en) 2005-09-19
MXPA04010173A (es) 2005-02-03
HK1067981A1 (en) 2005-04-22
CN1658874A (zh) 2005-08-24
JP2005529116A (ja) 2005-09-29
ATE389406T1 (de) 2008-04-15
AU2003223627B2 (en) 2006-10-12
DE60319813T2 (de) 2009-04-23
CA2481940A1 (en) 2003-10-30
NZ535763A (en) 2007-06-29
RU2004133764A (ru) 2005-07-20
ZA200407984B (en) 2005-10-18
SI1499316T1 (sl) 2008-08-31
KR20040099445A (ko) 2004-11-26
ES2301791T3 (es) 2008-07-01
AU2003223627A1 (en) 2003-11-03
AU2003223627C1 (en) 2003-11-03
KR100827470B1 (ko) 2008-05-06
ECSP045367A (es) 2004-11-26
IL164584A0 (en) 2005-12-18
JP4384918B2 (ja) 2009-12-16
TW200306183A (en) 2003-11-16
DE60319813D1 (de) 2008-04-30
PE20040684A1 (es) 2004-10-05
EP1499316B1 (en) 2008-03-19
WO2003088967A1 (en) 2003-10-30
CN100522166C (zh) 2009-08-05
DK1499316T3 (da) 2008-07-21
PT1499316E (pt) 2008-06-30

Similar Documents

Publication Publication Date Title
CY1110363T1 (el) Παραγωγα (1-4-πιπεριδινυλ)βενζιμιδαζολιου χρησιμα σαν ανταγωνιστες η3 ισταμινης
CY1105986T1 (el) Παραγωγα ινδολιου χρησιμα ως ανταγωνιστες η3 ισταμινης
CY1109401T1 (el) Παραγωγα πιπεριδινης ως ανταγωνιστες του δεκτου nmda
CY1105621T1 (el) Νεα ετεροκυκλικα παραγωγα φθορογλυκοζιτου, φαρμακα που περιεχουν τις ενωσεις αυτες και η χρηση τους
CY1108754T1 (el) Νεα παραγωγα θειοφαινογλυκοσιδης, μεθοδος για την παρασκευη τους, φαρμακα περιεχοντα αυτες τις ενωσεις και η χρηση τους
MY132566A (en) Benzimidazolone histamine h3 antagonists
CY1116103T1 (el) Υποκατεστημενα παραγωγα 1,2,3,4-τετραϋδροϊσοκινολινης
CY1118128T1 (el) Αρυλ διϋδροπυριδινονες και πιπεριδiνονες ως αναστολεις του mgat2
CY1113450T1 (el) Διαμινοπυριμιδινες ως ρ2χ3 και ρ2χ2/3 ανταγωνιστες
CY1124496T1 (el) Οξυστερολες και μεθοδοι χρησης αυτων
CY1114708T1 (el) Παραγωγα πυραζολο-κιναζολινης, διαδικασια για την παρασκευη τους και η χρηση τους ως αναστολεων κινασης
CY1109677T1 (el) Παραγωγα κινολινης και χρηση αυτων ως μυκοβακτηριακων αναστολεων
CY1110863T1 (el) Παραγωγα του 2-(8,9-διοξο-2,6-διαζαδικυκλο (5.2.0)-εννε-1(7)-εν-2-υλ)αλκυλ-φωσφονικου οξεος και η χρηση τους ως ανταγωνιστων του ν-μεθυλ- d-ασπαρτικου (nmda) υποδοχεα
CY1105617T1 (el) Νεα αρωματικα παραγωγα των φθορογλυκοσιδων, φαρμακα περιεχοντα αυτες τις ενωσεις και η χρηση τους
CY1112286T1 (el) Παραγωγα πυραζολιου χρησιμα για τη θεραπεια γυναικολογικων ασθενειων
CY1109227T1 (el) Παραγωγα της 5-φαινυλο-4-μεθυλο-θειαζολ-2-υλ-αμινης ως αναστολεις των ενζυμων κινασης της φωσφατιδυλινοσιτολης 3 (p13) για την θεραπεια των φλεγμονωδων ασθενειων των αεραγωγων
CY1125016T1 (el) Διαμορφωτες υποδοχεα πιπεριδινης cxcr7
CY1106679T1 (el) Αζαδικυκλικες ετεροκυκλικες ενωσεις ως τροποποιητες κανναβινοειδους υποδοχεα
CY1117584T1 (el) Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, cx3cr1
CY1105227T1 (el) Ενωσεις πιπepιδινης ως αντιαλλepγικα
CY1106598T1 (el) Παραγωγα κινολινης και ισοκινολινης, μεθοδος για την παραγωγη αυτων και χρηση αυτων ως αντιφλεγμονωδη μεσα
CY1109656T1 (el) Υποκατεστημενα παραγωγα μορφολινης και θειομορφολινης
CY1111425T1 (el) ΠΑΡΑΓΩΓΑ ΤΗΣ ΠΥΡΙΔΟ[2,1-a]-ΙΣΟΚΙΝΟΛΙΝΗΣ ΩΣ DPP-IV ΑΝΑΣΤΟΛΕΙΣ
NO20060664L (no) N-substituerte benzimidazolyl C-kit inhibitorer
CY1107281T1 (el) Παραγωγα τροπανιου υποκατεστημενα με ιδιδαζοπυριδινη με ενεργοτητα ανταγωνιστη ccr5 υποδοχεα για τη θεραπεια hiv και φλεγμονης